GSK ex­pe­dites Blenrep time­lines as it eyes sec­ond chance in mul­ti­ple myelo­ma

GSK wants to present Blenrep to reg­u­la­to­ry bod­ies soon­er.

The UK phar­ma will sub­mit Blenrep in sec­ond-line mul­ti­ple myelo­ma to US, Eu­ro­pean and Japan­ese au­thor­i­ties …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER